Head-to-head studies have shown that drug-eluting stents infused with medicine to keep the artery from re-narrowing perform better than bare metal stents in patients treated for coronary artery disease. A 2005 study by Dr. Charles Simonton showed similar outcomes in the general population of patients for the two types of medicated stents currently being used in the United States.
Dr. Simonton and the STENT Group of eight coronary intervention centers have examined how the sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) performed in patients with diabetes. The STENT Group is the first prospective, consecutive, multi-center registry for drug-eluting stents in the U.S., which began enrollment in May 2003. More than 80 percent of all interventions are enrolled at the eight sites, with nine-month clinical follow-up achieved in 94 percent of patients.
A total of 1,680 diabetic patients undergoing either pure PES or pure SES procedures (i.e. no other vessels treated with other devices) were enrolled and completed nine-month follow up. Of the 498 insulin-treated diabetic patients, 235 received PES and 263 received SES. Of the remaining non-insulin-treated diabetic patients (1,182 pts), 570 received PES and 612 received SES. While PES-treated patients more frequently had high-risk or longer lesions and vessels